Please ensure Javascript is enabled for purposes of website accessibility

What You'll Want to Know About Exact Sciences' Q1 Earnings

By Keith Speights - Updated May 1, 2019 at 6:12AM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The maker of the Cologuard colorectal cancer screening test reported tremendous revenue growth -- but a worsening bottom line.

The last time Exact Sciences (EXAS -1.54%) announced its quarterly results, revenue increased 64% compared with the prior-year period. It was a different story on the company's bottom line, though, with a widening net loss.

Any questions that investors had about Exact Sciences' first quarter were answered when the company announced its Q1 results after the market closed on Tuesday. Here's what you need to know from the company's quarterly update.

Cologuard test kit and packaging

Image source: Exact Sciences.

By the numbers

Exact Sciences announced Q1 revenue of $162 million, a 79% increase from the $90 million reported in the same quarter of the previous year. The company's reported revenue handily beat the average analysts' revenue estimate of $153.04 million.

How did Exact Sciences' bottom line look in the first quarter? The company reported a GAAP net loss of $83 million, or $0.66 per share, versus a loss of $39 million, or $0.33 per share, in the same period in 2018. Analysts were expecting a net loss in Q1 of $0.65.

The company ended the first quarter with cash, cash equivalents, and marketable securities totaling $1.3 billion. This cash stockpile was bolstered by the issuance of new convertible notes that raised $236 million.

Behind the numbers

As always, the key factor driving Exact Sciences' results was the performance of its Cologuard colorectal cancer screening test. And the performance for Cologuard in Q1 was very good.

Exact Sciences reported a 79% increase in test volume in the first quarter, with around 334,000 people screened using Cologuard. That percentage growth matched up exactly with the company's revenue increase.

There were a couple of things worth noting, though. Average recognized revenue per test for Cologuard slipped $2 to $483. At the same time, the company's average cost per test increased by $4 to $128.

While Exact Sciences' revenue soared, its bottom line got worse. Why? The company's operating expenses jumped a whopping 80% year over year to $187 million in the first quarter. It spent more money on research and development costs, sales and marketing, and general and administrative costs. But at this stage for Exact Sciences, increasing spending isn't a major concern.

Looking ahead

Exact Sciences boosted its full-year 2019 guidance. The company now projects revenue to be between $725 million and $740 million, compared with its prior guidance of $710 million to $730 million. 

CEO Kevin Conroy said that "the strong start to 2019 gives us confidence our investments in people, facilities, and partnerships will help us achieve our goal of screening at least 40% of the eligible U.S. population with Cologuard." Exact Sciences' partnership with Pfizer and its greater focus on customer care could enable the company to make headway on this goal in the coming quarters.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Exact Sciences Corporation Stock Quote
Exact Sciences Corporation
EXAS
$53.17 (-1.54%) $0.83

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning service.

Stock Advisor Returns
330%
 
S&P 500 Returns
115%

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 05/22/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.